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Abstract
Background: While lung transplantation is an increasingly utilized therapy for advanced lung diseases, chronic
rejection in the form of Bronchiolitis Obliterans Syndrome (BOS) continues to result in significant allograft
dysfunction and patient mortality. Despite correlation of clinical events with eventual development of BOS, the
causative pathophysiology remains unknown. Airway epithelial cells within the region of inflammation and fibrosis
associated with BOS may have a participatory role.
Methods: Transplant derived airway epithelial cells differentiated in air liquid interface culture were treated with
IL-1b and/or cyclosporine, after which secretion of cytokines and growth factor and gene expression for markers of
epithelial to mesenchymal transition were analyzed.
Results: Secretion of IL-6, IL-8, and TNF-a, but not TGF-b1, was increased by IL-1b stimulation. In contrast to
previous studies using epithelial cells grown in submersion culture, treatment of differentiated cells in ALI culture
with cyclosporine did not elicit cytokine or growth factor secretion, and did not alter IL-6, IL-8, or TNF-a
production in response to IL-1b treatment. Neither IL-1b nor cyclosporine elicited expression of markers of the
epithelial to mesenchymal transition E-cadherin, EDN-fibronectin, and a-smooth muscle actin.
Conclusion: Transplant derived differentiated airway epithelial cell IL-6, IL-8, and TNF-a secretion is not regulated
by cyclosporine in vitro; these cells thus may participate in local inflammatory responses in the setting of
immunosuppression. Further, treatment with IL-1b did not elicit gene expression of markers of epithelial to
mesenchymal transition. These data present a model of differentiated airway epithelial cells that may be useful in
understanding epithelial participation in airway inflammation and allograft rejection in lung transplantation.
Background
Lung transplantation is an accepted therapeutic
approach to selected end-stage lung diseases. Despite
improvement in peri-operative and early post-transplant
outcomes, lung transplant recipients do not obtain the
equivalent allograft longevity and resultant survival con-
ferred upon other solid organ recipients [1]. Long-term
outcomes in lung transplantation have been complicated
by chronic rejection in the form of Bronchiolitis Obliter-
ans Syndrome (BOS) with 50% of patients affected at
five years [2,3].
Clinical events that correlate with the eventual devel-
opment of BOS include primary graft dysfunction, acute
rejection, viral respiratory infections, and gastroesopha-
geal reflux although the mechanisms by which these
events contribute to BOS have not been discerned [4].
While the histopathology of BOS has been described, a
complete understanding of the causative pathophysiol-
ogy remains elusive. Early inflammatory lesions in BOS
are characterized by bronchiolar epithelial invasion by
mononuclear cells with marked neutrophilia. After reso-
lution of inflammation, fibrosis of the epithelium and
airway lumen become the dominant histopathology [5].
Murine tracheal transplantation models suggest that
airway epithelial cells (AEC) are a target of immune
mediated injury in BOS [6]. Sera from lung transplant
recipients with BOS have been shown to contain
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AEC [7,8]. Binding of these HLA antibodies to AEC
lines elicits production of fibrogenic growth factors with
subsequent fibroblast proliferation, suggesting that
airway epithelial cells may have a role in transforming
an alloimmune signal into a fibrotic process [9]. This
transformation from inflammation to fibrosis occurs at
or near the epithelium and may be part of the pathology
of BOS.
While research suggesting a role for AEC in the
pathophysiology of BOS has focused primarily upon
alloimmune processes, less attention has been directed
toward the innate inflammatory response of the epithe-
lium to the local dynamic environment. Unlike other
transplanted solid organs, the pulmonary allograft and
airway epithelium are exposed to 10,000 liters of envir-
onmental air and its contents daily [10]. The potential
role of AEC to participate in and direct innate immunity
through secretion of cytokines, such as IL-6, IL-8, and
TNF-a, and growth factors such as TGF-b1, in response
to this dynamic local milieu is well established, but the
ability of these factors to participate in dysregulated
inflammation in the setting of systemic immunosuppres-
sion and, thereby, contribute to the genesis of BOS has
not been investigated in lung transplantation [11].
Previous investigation has demonstrated a differing
impact of immunosuppressive agents upon AEC cyto-
kine and growth factor secretion in vitro, depending
upon the experimental approach [12-15]. One important
agent is cyclosporine, a calcineurin inhibitor used in
combination with other agents in lung transplantation.
Airway epithelial cells express cyclophilin, the cytosolic
receptor for cyclosporine, and treatment of primary
AEC grown in submersion culture with cyclosporine
leads to inhibition of proliferation and increases in
IL-1b stimulated IL-8 release [13]. Other studies using
alveolar and central airway epithelial cell lines [15]
suggest that calcineurin inhibitors can up-regulate IL-6
and IL-8 production. However, the effect of calcineurin
inhibitors on epithelial cell function may depend on the
state of differentiation and presence of cell subtypes
typically not present in submersion culture, such as
ciliated and goblet cells.
The growth factor TGF-b1, a potent stimulator of
lung fibroblast proliferation and extracellular matrix
production [16] and differentiation into myofibroblasts
[17], also can induce epithelial to mesenchymal transi-
tion (EMT) to a myofibroblast-like phenotype in human
AEC, [16-18] as suggested by de novo or increased
expression of tenascin C, alpha-smooth muscle actin
(SMA) and EDN-fibronectin and concomitant decreased
expression of the epithelial-specific marker E-cadherin
[18]. This transformation may be a critical step in the
process of obliterative bronchiolitis in chronic lung
allograft rejection in a process similar to that seen in
other fibrotic lung diseases such as idiopathic pulmon-
ary fibrosis [19,20]. One prior study demonstrated the
expression of EMT markers in epithelial cells collected
by bronchoscopy from stable lung transplant recipients
[21], suggesting the presence of EMT and airway remo-
deling is associated with the clinical presentation of
BOS [22]. In addition, cytokines such as TNF-a have
recently been shown to potentiate the effect of TGF-b1
towards EMT in epithelial cells [23-25]. Taken together,
these data suggest that a certain milieu of cytokines and
growth factors must be present to elicit EMT sufficient
to cause pathological changes to airways.
We hypothesized that cyclosporine would alter the
secretion of selected cytokines and growth factors, and
potentially alter the process of EMT, in AEC collected
from lung transplant recipients. To answer this question,
we collected cells from lung transplant recipients by
endobronchial brushing and grew these cells in air
liquid interface (ALI) culture to force differentiation and
the development of goblet and ciliated cells. Our data
demonstrate that cyclosporine does not attenuate the
secretory response of airway epithelial cells to a stan-
dard stimulus, IL-1b. These results suggest that cyclos-
porine in physiologic, non-toxic concentrations has little
effect on secretion of cytokines and growth factors by
differentiated AEC. In addition, neither IL-1b nor
cyclosporine induced gene expression of markers
characteristic of epithelial to mesenchymal transition.
Cyclosporine does not regulate key cytokine secretory
functions in differentiated AEC that are associated
with BOS.
Materials and methods
Patients
The recruitment of lung transplant recipients and the
use of primary human airway epithelial cells collected
by bronchoscopy in these patients were approved by the
University of Chicago Institutional Review Board.
Patients were recruited for this study from the popula-
tion of lung transplant recipients at the University of
Chicago. Nine patients, age 25 to 64 years, participated
through the period of the current study undergoing a
total of 12 bronchoscopies. The indications for trans-
plantation included idiopathic pulmonary fibrosis (N =
4), chronic obstructive pulmonary disease (N = 3, one
with both IPF and COPD), and one patient each with
cystic fibrosis, eosinophilic granuloma, and alpha-1 anti-
trypsin deficiency. All patients were between 3 and 12
months post-transplant and were clinically stable under-
going outpatient surveillance bronchoscopy. Patients
underwent standard immunosuppression per protocol,
which did not include cyclosporine. Pathologic evalua-
tion of transbronchial biopsies collected at the time of
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tion with only one episode greater than A1. Addition-
ally, culture of bronchoalveolar lavage collected at the
time of sampling was notable for significant isolation of
specific organisms in three patients, including Mycobac-
terium avium intracellulare, Mycobacterium gordonae,
and Pseudomonas aeruginosa. Neither rejection nor iso-
lation of an organism impacted the ability to culture air-
way epithelial cells over baseline.
Bronchoscopy
Informed consent was obtained from each subject prior
to participation. Conscious sedation was employed with
midazolam and fentanyl, and vital signs were monitored
throughout the procedure. After inspecting both lungs
and the anastomoses, bronchoalveolar lavage was
obtained from either the right middle lobe or lingula.
Following this, two cytology brushings with a protected
epithelial cell cytology brush (Medical Engineering
Laboratory, Shelby, NC) were collected from subseg-
mental bronchi and immediately placed in Clonetics
media consisting of Bronchial Epithelial Cell Basal
Media and SingleQuots supplements and growth factors
(Lonza, Walkersville MD). Transbronchial biopsies were
then done for both clinical and research indications. All
patients recovered uneventfully from bronchoscopy.
Airway epithelial cell culture
We have previously described our cell culture methods
[26]. Brushes were placed in supplemented Clonetics
media and gently shaken. This media was set aside and
then supplemented Clonetics was titrated against the
cytology brushes to ensure maximal harvesting of
epithelial cells. Both samples were then centrifuged for
three minutes at 1500 rpm and pelleted. Pellets were
then resuspended in 2 ml of supplemented Clonetics
media with a final antimicrobial regimen consisting of
50 μg/ml amphotericin, 50 μg/ml gentamicin, 100 U/ml
penicillin, and 100 μg/ml streptomycin and plated in
collagen-IV coated T25 flasks. After two days a further
3 ml of supplemented Clonetics media was added. On
day four, the media was changed and subsequently
changed every two days until cells were 85% confluent.
Cells were passed to collagen-IV coated T75 flasks for
further expansion and then were transferred (passage 2)
to 12-well transwell filter membranes (10
5/well) coated
with collagen-IV. Cells were grown in ALI media con-
sisting of 1:1 supplemented Clonetics and DMEM (Med-
iatech, Manassas VA) supplemented with 50 nM
retinoic acid, 130 mg/L bovine pituitary extract, and
50 ug/ml low-endotoxin BSA. Cells were fed both apically
and basally every 48 hr until confluence was achieved.
Cells then were transitioned to ALI conditions and were
only fed through the transwell basal compartment with
the apical compartment exposed to air. Cells were fed
every 48 hr for three weeks.
Demonstration of cell differentiation
We have previously described these methods [26]. To
demonstrate cell differentiation in air liquid interface
culture, immunofluoresence labeling and confocal
microscopy were utilized. Epithelial cells in ALI culture
× 3 wk were fixed with 4% paraformaldehyde and then
stained with antibodies directed against cytokeratin-5
(CK-5, clone RCK103, Santa Cruz Biotechnology, Santa
Cruz CA) marking basal cells, Mucin 5AC (clone C-20,
Santa Cruz Biotechnology, Santa Cruz CA) binding
goblet cells and b-tubulin (catalogue # ab6046, Abcam
Inc., Cambridge, MA) marking ciliated cells. Epithelial
cell purity was determined using an anti-vimentin (clone
V9, ZYMED Laboratories, Carlsbad CA) antibody to
detect contaminating fibroblasts, and an anti-CD68
antibody (clone KP1, Dako, Carpinteria CA) to detect
contaminating alveolar macrophages with IMR-90 pri-
mary lung fibroblast cell line and cytospin preparations
of bronchoalveolar lavage specimens as positive controls,
respectively.
Treatment with IL-1b and cyclosporine
All cells were at passage two and in ALI culture for at
least 15 days prior to initiation of the experimental pro-
tocol. Interleukin-1b was selected as a stimulus to exam-
ine epithelial cell cytokine secretion as it elicits secretion
of both IL-8 [19,20] and IL-6 [21,22] from cultured
AEC. Experimental arms consisted of treatment with 10
ng/ml IL-1b (R and D Systems, Minneapolis MN) alone,
1000 ng/ml cyclosporine (Sigma-Aldrich, St. Louis MO)
alone, both IL-1b and cyclosporine, or control vehicle
(0.01% ethanol). Each intervention was tested separately
in the apical and basal compartments and assayed in tri-
plicate. Cells in the vehicle and cyclosporine arms were
treated daily over the five-day protocol with appropri-
ately supplemented culture media. The IL-1b arms were
treated daily with media for the first four days and
received IL-1b supplemented media on the fifth day.
Cells receiving both IL-1b and cyclosporine were treated
with media plus cyclosporine for the first four days and
on the fifth day received media supplemented with both
cyclosporine and IL-1b. On day 6 (21 days of ALI cul-
ture), samples were collected for assays. The apical side
of the cell layer was washed with 200 μl of ALI medium.
The conditioned media from the basal compartment was
retrieved. The cell layers were harvested, washed, and
pelleted. All samples were stored at -80°C until use.
Quantification of cytokine and growth factor secretion
IL-6, IL-8, TNF-a and TGF-b1 concentrations in
conditioned media from the basal compartment were
Floreth et al. Respiratory Research 2011, 12:44
http://respiratory-research.com/content/12/1/44
Page 3 of 9determined via ELISA (R and D Systems, Minneapolis
MN) for each factor following kit directions. Samples were
diluted as required. Blank, non-conditioned ALI was
assayed at the same time to ensure that detected IL-6, IL-
8, TNF-a and TGF-b1 concentrations represented secre-
tion from cells.
Real-time reverse transcription-polymerase chain reaction
Total RNA was isolated from cells using a PerfectPure
RNA 96 Cell Kit (5 Prime, Gaithersburg, MD) following
the manufacturer’s protocol. Samples were treated with
DNase I (5 Prime). Total RNA was reverse transcribed
using random primers and Superscript II reverse tran-
scriptase (Invitrogen, Carlsbad, CA). Real-time RT-PCR
was performed using a Bio-Rad iCycler iQ PCR Detec-
tion System using iQ Supermix (Bio-Rad, Hercules, CA),
and gene-specific primers as listed in Table 1.
Statistics
Cytokine secretion data are expressed as the mean ±
SEM. Real-time RT-PCR data are expressed as fold-
change from control using GAPDH as an internal stan-
dard. Differences in cytokine secretion were examined
by analysis of variance; when significant differences were
found, post-hoc analysis was done using Fisher’sp r o -
tected least significant difference test. Differences in
gene expression from control were examined using the
95% confidence interval. Differences were considered
significant when P < 0.05.
Results
Cell Culture and Differentiation
Cells were collected from twelve bronchoscopies on nine
patients. Eight of these from eight different patients
yielded viable cells that w e r eg r o w ni ns u b m e r s i o n
culture, successfully expanded, and then differentiated in
ALI culture. All differentiated cells maintained cell
layer integrity throughout the experimental protocol
(Figure 1).
Labeling and confocal microscopy demonstrated the
simultaneous presence of all three major AEC types:
basal cells, goblet cells, and ciliated cells (Figure 1).
Staining for CD68 was negative in cells at ALI demon-
strating absence of macrophages. Staining for vimentin
demonstrated less than 1% labeling in cells maintained
in ALI cultures for 3 wk. Double staining techniques
demonstrated that cells that labeled for vimentin did
not label for CK-5, MUC5AC, or b-tubulin, thus sug-
gesting minimal residual contamination with fibroblasts
from the original collection.
Secretion of IL-8
Stimulation with IL-1b in either the apical or basal com-
partment significantly up-regulated IL-8 secretion to the
basal compartment: the concentration after basal IL-1b
treatment was 117 ± 24 ng/ml (vs 55 ± 13 ng/ml for
control, P = 0.03), whereas the concentration after apical
IL-1b treatment was 92 ± 19 ng/ml (vs 32 ± 7 ng/ml for
control, P = 0.01) (Figure 2). Treatment with cyclospor-
ine in either the basal or apical compartment had no
impact upon IL-8 secretion when compared with con-
trol vehicle, and further did not impact IL-1b stimulated
differentiated airway epithelial cell secretion of IL-8
(Figure 2). In addition, there was no significant differ-
ence in IL-8 secretion either basal or apically between
those treated with IL-1 b alone versus those with IL-1 b
and cyclosporine (P = NS; Figure 2).
Secretion of IL-6
As with IL-8, stimulation with IL-1b in either the apical
or basal compartment significantly up-regulated IL-6
secretion in the basal compartment: the concentration
with basal IL-1b treatment was 246 ± 45 pg/ml (vs 40 ±
12 pg/ml for control, P = 0.001), whereas the concentra-
tion with apical IL-1b treatment was 167 ± 58 pg/ml
(vs 9.0 ± 4.4 pg/ml for control, P = 0.002) (Figure 3). As
with IL-8, cyclosporine treatment altered neither
baseline release nor IL-1b stimulated release of IL-6
(Figure 3). In addition, there was no significant differ-
ence in IL-6 secretion either basal or apically between
those treated with IL-1 b alone versus those with IL-1 b
and cyclosporine (P = NS; Figure 3).
Secretion of TNF-a
As with the other interleukins, stimulation with IL-1 b
in either the apical or basal compartment significantly
up-regulated secretion of TNF-a in the basal compart-
ment: the concentration with basal IL-1 b treatment was
Table 1 Primers used for real-time RT-PCR
Gene Forward Reverse
E-cadherin 5’-CGGGAATGCAGTTGAGGATC-3’ 5’-AGGATGGTGTAAGCGATGGC-3’
a-SMA 5’-CTGGCATCGTGCTGGACTCT-3’ 5’- GATCTCGGCCAGCCAGATC-3’
EDA-FN 5’-GAGCTATTCCCTGCACCTGATG-3’ 5’-CGTGCAAGGCAACCACACT-3’
TGF-b 5’-ACCGGCCTTTCCTGCTTCTCA-3’ 5’-CGCCCGGGTTATGCTGGTTGT-3’
GAPDH 5’-AGCCACATCGCTCAGACACCA-3’ 5’-GCAAATGAGCCCCAGCCTTC-3’
SMA, smooth muscle actin, FN, fibronectin, TGF, transforming growth factor.
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apical IL-1b treatment was 22 ± 7.6 pg/ml (vs 0.0 ±
0.0 pg/ml for control, P = 0.0001) (Figure 4). As with
IL-6 and IL-8, cyclosporine treatment altered neither
baseline release nor IL-1b stimulated release of IL-6
(P = NS; Figure 4).
Secretion of TGF-b1
TGF-b1 concentrations in cell-conditioned medium, for
any experimental intervention, were not higher than
that found in bland medium (data not shown).
Gene expression of TGF-b
Expression of TGF-b also did not differ after treatment
of differentiated AEC with IL-1b, cyclosporine or the
combination over 24 hr when added to the basal
compartment of the ALI culture (Figure 5). Addition of
IL-1b to the apical compartment elicited a 2.1 ± 0.3 fold
increase in TGF-b expression which was not seen when
cells were treated with either cyclosporine alone or the
combination of IL-1b and cyclosporine (Figure 5).
Gene expression of EMT markers
Expression of the myofibroblast markers a-smooth
muscle actin (SMA) and EDN-fibronectin, and the epithe-
lial cell marker E-cadherin, as measured by real-time
RT-PCR following each experimental intervention to the
basal compartment of the ALI culture was not different
than that found in control, differentiated AEC (Figure 6).
Addition of IL-1b to the apical compartment decreased
EDN-fibronectin expression significantly; this was not
seen when cells were treated with either cyclosporine
alone or the combination of IL-1b and cyclosporine
(Figure 6).
Discussion
Long-term allograft survival in lung transplantation is
limited by BOS, in which epithelial inflammation and
fibrosis over time becomes a prominent component [3].
Epithelial cell secretion of chemotactic factors for neutro-
phils, such as IL-8 [27,28] and IL-6 [29], and pro-fibrotic
f a c t o r ss u c ha sT G F - b [27] and TNF-a, participate in
overall small airway obliteration over time. In this study,
we demonstrate that the potent immunosuppressive,
Figure 1 Pulmonary allograft epithelial cells in culture.A .
Phase-contrast image of cells in submersion culture. B. Phase-
contrast image of cells in air liquid interface culture for 3 weeks. C
and D. Confocal microscopy of air liquid interface cells at 3 weeks.
Cells were labeled with antibodies directed against ciliated cells
(blue), goblet cells (red), or basal cells (green). White represents the
overlap of all three colors and denotes an indeterminate cell.
Original magnification of for A and B, 40 ×, and C and D, 400 ×.
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Figure 2 Secretion of IL-8 by transplant-derived airway
epithelial cells after stimulation with IL-1b and cyclosporine.A .
IL-8 secretion in basal medium after basal stimulation. *, P = 0.03 for
IL-1b vs. control; †, P = 0.04 for IL-1b and cyclosporine vs.
cyclosporine alone. B. IL-8 secretion in basal medium after apical
stimulation. *, P = 0.006 for IL-1b vs. control; † P = 0.03 for IL-1b
and cyclosporine vs. cyclosporine alone. N = 5 unique patient
samples.
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TNF-a and TGF-b after stimulation with a known secre-
togogue for both IL-8 and IL-6, IL-1b, nor does it elicit
expression of factors known to be associated with epithe-
lial-mesenchymal transition. These data suggest that
cyclosporine neither suppresses nor up-regulates pro-
cesses critical to the genesis of BOS.
Of significant importance, we demonstrated that in
contrast to studies using cells grown in submersion cul-
ture [12,13,15] cyclosporine did not increase IL-6 and
IL-8 production in differentiated, transplant-derived air-
way epithelial cells. Airway epithelial cells have been
shown to contain cyclophilin, the cytosolic receptor for
cyclosporine, [13] and thus may regulate epithelial func-
tion in a manner similar to that seen in lymphocytes.
The ability of AEC to respond to appropriate stimuli
with production of inflammatory mediators despite
cyclosporine administration suggests that even in immu-
nosuppressed lung transplant patients, AEC may release
inflammatory mediators in response to environmental
stimulation without regulation by the immunosuppres-
sive agent cyclosporine, and further suggests that
mechanisms by which cyclosporine modulates the devel-
opment of BOS does not include modulation of inflam-
matory factors secreted by AEC.
To the best of our knowledge, our study represents
the first report of primary airway epithelial cells from
lung transplant recipients grown in air liquid interface
culture with resultant differentiation into mucous pro-
ducing goblet, ciliated and basal cells. The use of ALI
culture permits challenge to either the apical or basal
cell layer surface. The apical (air exposed) surface, cov-
ered with goblet cell produced mucous, models the air-
way lumen while the matrix-coated filter approximates
the basement membrane. Media supplied through the
basal compartment delivers agents, nutrients, and poten-
tial irritants. This differentiation and polarity create a
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Figure 3 Secretion of IL-6 by transplant-derived airway
epithelial cells after stimulation with IL-1b and cyclosporine.
A. IL-6 secretion in basal medium after basal stimulation. *, P < 0.0001
for IL-1b vs. control and for IL-1b and cyclosporine vs. cyclosporine
alone. B. IL-6 secretion in basal medium after apical stimulation.
*, P = 0.002 for IL-1b vs. control; †,P=0 . 0 2f o rI L - 1 b and cyclosporine
vs. cyclosporine alone. N = 5 unique patient samples.
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Figure 4 Secretion of TNF-a by transplant-derived airway
epithelial cells after stimulation with IL-1b and cyclosporine.A .
TNF-a secretion in basal medium after basal stimulation. *, P <
0.0001 for IL-1b vs. control and for IL-1b and cyclosporine vs.
cyclosporine alone. B. TNF-a secretion in basal medium after apical
stimulation. *, P = 0.0001 for IL-1b vs. control and for IL-1b and
cyclosporine vs. cyclosporine alone. N = 5 unique patient samples
except for apical stimulation with both IL-1b and cyclosporine, for
which N = 3.
Floreth et al. Respiratory Research 2011, 12:44
http://respiratory-research.com/content/12/1/44
Page 6 of 9useful model of airway epithelium that differs from sub-
mersion culture techniques in which cells maintain a
basal cell phenotype forming monolayers that can only
be fed and challenged from a single cell surface.
Previous investigations utilizing non-transplant airway
epithelial cells demonstrate that in the setting of immu-
nosuppression, cells grown in ALI cell culture condi-
tions respond to stimuli in a manner different than that
seen in cells grown in submersion culture [13-15].
Given that differentiated cells must utilize resources and
energy to maintain their unique phenotypes and interact
with diverse surrounding cell populations, they may
respond to stimuli in a different fashion than cell mono-
layers in submersion culture. In addition, not only do
the cells present in differentiated culture differ in type
and proportion but the environment in which each indi-
vidual cell type must respond to stimuli differs as well.
Immunofluorescent labeling demonstrated the presence
of all three cell types: ciliated, goblet, and basal. Control
staining demonstrated the lack of macrophages as CD68+
labeled cells were not present after ALI culture × 3 wk.
This is a useful advantage compared to cells grown in sub-
mersion culture, in which macrophages persisted up to at
least passage 2 [30]. Further, few contaminating fibroblasts
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Figure 5 Expression of TGF-b1 in transplant-derived
differentiated airway epithelial cells. Expression after either basal
(Figure 5A) or apical (Figure 5B) addition of mediators is shown. N =
5 unique patient samples for each. *, P < 0.05 versus vehicle
control. CSA, cyclosporine.
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Figure 6 Expression of markers of epithelial-mesenchymal
transformation in transplant-derived differentiated airway
epithelial cells. Expression after either basal or apical addition of
mediators is shown. A. Expression of a-smooth muscle actin (SMA).
B. Expression of EDN-fibronectin. C. Expression of E-cadherin. N = 5
unique patient samples. *, P < 0.05 versus vehicle control. CSA,
cyclosporine, SMA, smooth muscle actin, FN, fibronectin.
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tions of Forrest, et al, who previously demonstrated a lack
of fibroblast contamination in transplant-derived epithelial
cells grown in submersion culture [30]. The use of differ-
entiated AEC devoid of other, contaminating cell types is a
useful advantage to examine the response to immunosup-
pressive agents in isolation in AEC.
We demonstrated that differentiated airway epithelial
cells collected from lung transplant recipients can
respond to stimuli such as IL-1b to secrete cytokines
such as IL-6, IL-8, and TNF-a, which then may modify
further the local microenvironment. IL-8 is an impor-
tant chemokine leading to neutrophil chemotaxis and
IL-6 has been associated with early inflammation in the
setting of tissue damage. TNF-a not only plays a central
role inflammation but also in apoptosis. It has been
shown that IL-1b m a yi n c r e a s et h en u m b e ro fT N F
receptors, but the finding that this cytokine can induce
TNF-a secretion in differentiated human AEC is also
novel [31]. Each of these processes may be important in
the pathogenesis of BOS. Our data suggest the possibi-
lity that airway epithelium may be more than just a tar-
g e to fi n j u r yi nB O Sb u tm a yp a r t i c i p a t ei nc r e a t i n go r
perpetuating an inflammatory milieu at the interface
between the lungs and the environment, the anatomic
interface where BOS localizes.
One potential mediating role of the airway epithelium
to injury and disordered repair in the pathogenesis of
BOS may be stimulation of fibroblast proliferation, a
process that can be mediated by growth factors such as
TGF-b1. However, we were not able to demonstrate
TGF-b1 secretion by differentiated transplant AEC even
though gene expression was found to be increased when
stimulated apically. A prior paper utilizing AEC lines
showed only indirect evidence of fibrogenic growth fac-
tor secretion through utilization of blocking antibodies
in fibroblast proliferation studies; actual cytokine and
growth factor levels were not assayed [9]. Another limit-
ing factor in our observations is that TGF-b1h a sa
short half-life in acidic environments and thus may not
maintain structural integrity in conditioned media
where the latent form has nothing to bind to inhibit
rapid degradation [29].
One potential benefit of working with primary cells
from lung transplant recipients is that patient outcomes,
including early BOS, may be correlated with epithelial
cell function. Although the proportional magnitude of
response to stimuli appears similar, absolute quantities
of cytokine production vary between patients, leaving
open the possibility that patients whose epithelial cells
produce higher levels of cytokines may be more prone
to peribronchiolar inflammation and eventual BOS.
In our study, quantitative gene expression of a-SMA,
EDN-fibronectin, and E-cadherin were substantially
unchanged in response to IL-1b and/or cyclosporine,
suggesting that neither the inflammatory cytokines
added or produced by the AEC themselves nor the
immunosuppressive agent shifted the phenotype of dif-
ferentiated, transplant-derived AEC towards EMT.
Indeed, apical treatment with IL-1b elicited a decrease,
not increase, in EDN-FN (Figure 5), which would not be
expected if epithelial cells were shifting to a mesenchy-
mal phenotype. A prior study had noted changes even
in asymptomatic transplant patients, but examined mor-
phology of cells as a marker of EMT rather than gene
expression [16]. Another study has demonstrated that
EMT can occur in normal epithelial after stimulation
with TGF-b1 [15]. The lack of TGF-b1 expression in
our study may thereby explain the lack of EMT marker
expression in differentiated AEC. Therein, a threshold
dose or time above a threshold dose of TGF-b1 alone or
in combination with other cytokines such as TNF-a
may not have been met and thereby EMT may not have
occurred. Lastly, other key cell types such as neutrophils
and macrophages may need to be present in this milieu
to elucidate EMT. Further studies are needed to deline-
ate the process by which EMT occurs both ex-vivo and
in-vivo and therein ways to interrupt it may allow treat-
ment modalities in the future.
Conclusions
In summary, we demonstrate IL-6, IL-8, and TNF-a
secretion, but not TGF-b1 secretion, in response to
IL-1b s t i m u l a t i o ni nd i f f e r e n t iated AEC collected from
stable lung transplant recipients. Secretion is not
affected by treatment with cyclosporine in contrast to
studies using cells grown in submersion culture. In addi-
tion, neither treatment with IL-1b nor cyclosporine
induced gene expression that would be expected in
epithelial-mesenchymal transformation. Our study sug-
gests that transplant-derived AEC grown in differen-
tiated culture have a response to cytokines different
from that seen in similar cells grown in submersion cul-
ture. These responses may be useful in understanding
the role of airway epithelium in processes associated
with BOS and chronic allograft rejection.
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